Dec 19 (Reuters) - MiniMed Group, the diabetes business of medical device maker Medtronic (MDT.N) , filed for an initial public offering in the United States on Friday.
With capital markets set for the year-end holidays slowdown, corporate issuers are laying the groundwork for a potential roadshow launch in early 2026 when the IPO market kicks back into action.
Fuel distributor ARKO Petroleum and drug developer Aktis Oncology also publicly filed paperwork for a New York IPO on Friday.
MiniMed will list on the Nasdaq under the symbol “MMED”. Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are the lead underwriters for the IPO.

MiniMed Group, a diabetes business of Medtronic, filed for a US IPO, planning to list on Nasdaq under "MMED". The IPO is expected to launch in early 2026, with Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley as lead underwriters. Other companies, ARKO Petroleum and Aktis Oncology, also filed for New York IPOs.

Medtronic's MiniMed files for US IPO